All In Biotech

Drug Trial Radar · NCT04194125

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression

Last checked: Nov 20, 2026Latest source record: Nov 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

25

Planned (sponsor's estimate)

Start

Feb 1, 2019

Primary completion

Jun 30, 2021

Study completion Jan 31, 2022

Sponsor

Lead sponsor
University of Warmia and MazuryAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Maria Sklodowska-Curie National Research Institute of Oncology; Medical University of Warsaw; The Diagnostic and Therapeutic Center Gammed; Poland; National Center for Research and Development, Poland
First posted
Dec 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-randomized, phase II, open label study. The purpose of this study is to estimate Progression Free Survival (PFS) after treatment with Peptide Receptor Radionuclide Therapy (PRRT) 177Lu-DOTATOC standard dose (up to 4x7,4GBq 177Lu DOTATOC) in combination with capecitabine (CAP) and temozolomide (TEM) - CAPTEM. Patients with advanced, non-resectable and/or progressive gastro-entero-pancreatic neuroendocrine tumors, GEP-NET, (G1, G2), in selected cases with high proliferation index (Ki-67\> 20%, usually below 55%), NETG3, with overexpression of somatostatin receptor (SSTR positive) will be enrolled in the study.

Conditions

  • Neuroendocrine Tumors

Interventions

  • 177Lu-DOTATOCDrug

    Four administrations of 5,55GBq up to 7,4 GBq 177Lu-DOTATOC will be administered at 8-week intervals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS - Progression Free SurvivalTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centrum Diagnostyczno-Lecznicze Gammed

    Warsaw, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.